MRNA
Moderna, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website modernatx.com
- Employees(FY) 3900
- ISIN US60770K1079
Performance
+8.47%
1W
+17.68%
1M
+21.03%
3M
+67.99%
6M
+21.74%
YTD
-8.11%
1Y
Profile
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Investment Analysis Report: Moderna Inc. (MRNA)
Overview:
Moderna Inc. (MRNA) operates in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $36.78 billion. In this report, we will conduct a detailed analysis of MRNA's financial health, valuation, earnings and revenue growth, prof...
Technical Analysis of MRNA 2024-05-03
Overview:
In analyzing the technical indicators for MRNA over the last 5 days, we will delve into the trends, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key factors, we aim to offer valuable insights and predictions for the upcoming days.
Trend Indicator...
Recent News & Updates
- 2024-05-07 23:24
- 2024-05-07 10:36
- 2024-05-06 03:20
- 2024-05-05 03:00
- 2024-05-04 22:49
Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript(Insidermonkey)
- 2024-05-04 10:49
Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript(Insider Monkey)
- 2024-05-04 08:09
- 2024-05-04 01:01
Decoding Moderna Inc (MRNA): A Strategic SWOT Insight(GuruFocus.com)
- 2024-05-03 20:45
3 Growth Stocks You'll Kick Yourself for Not Buying Today(Investorplace)
- 2024-05-03 18:34
- 2024-05-03 07:55
- 2024-05-03 07:27
- 2024-05-03 07:19
- 2024-05-03 06:34
Moderna First Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
- 2024-05-03 06:24
- 2024-05-03 06:23
- 2024-05-03 04:42
Moderna reports $1.2bn net loss in Q1 2024(Pharmaceutical Technology)
- 2024-05-03 04:17
- 2024-05-03 03:58
Sector Update: Health Care Stocks Softer Late Afternoon(Yahoo Finance)
- 2024-05-03 03:04
- 2024-05-03 00:43
- 2024-05-02 23:33
- 2024-05-02 23:14
- 2024-05-02 23:14
Moderna Shares Jump After Better-Than-Expected Sales(Yahoo Finance)
- 2024-05-02 22:53
- 2024-05-02 22:47
- 2024-05-02 22:26
- 2024-05-02 22:19
Stocks to Watch Thursday: Carvana, NIO, Qualcomm, Peloton(Yahoo Finance)
- 2024-05-02 22:05
- 2024-05-02 20:26
Jefferies Adjusts Price Target on Moderna to $155 From $125(Yahoo Finance)
Page 1 of 10
previousnext